Actively Recruiting
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-02-05
304
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality. Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. Furthermore, it may have nephroprotective effects with a preferential vasoconstriction of the post-glomerular arteriole resulting in increased glomerular filtration The hypothesis of the present work is that low-dose arginine-vasopressin supplementation reduce posttransplant AKI in liver transplantation.
CONDITIONS
Official Title
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years
- Scheduled for liver transplantation
- Able to provide signed informed consent after receiving clear information about the study
- Affiliated with Social Security
You will not qualify if you...
- Super-emergency liver transplantation or fulminant hepatitis
- Listed for or receiving simultaneous liver-kidney transplantation
- End-stage kidney disease with eGFR < 15 mL/min/1.73 m2 or needing dialysis before liver transplant
- History of epilepsy
- Allergy to arginine-vasopressin or its ingredients
- Refusal to participate
- Unable to provide informed consent due to language barrier
- Adults under guardianship or deprived of liberty
- Enrolled in another interventional clinical study
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
URC Lariboisière-Fernand Widal-saint Louis
Paris, France, 75010
Actively Recruiting
Research Team
J
Jacques DURANTEAU, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here